{
  "id": 10958408,
  "title": "STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial",
  "url": "https://urgent.news/2026/09/30/stat-eli-lillys-zepbound-combined-with-amylin-drug-led-to-significant",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-30T14:15:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/30/eli-lilly-zepbound-amylin-combination-drug-study/"
  },
  "original_language": "en",
  "account": "Eli Lilly's investigational combination therapy involving their blockbuster GLP-1 drug Zepbound and amylin hormone-targeting candidate eloralintide showed promising results in a mid-stage study. When tested in people with obesity and type 2 diabetes, the combination therapy led to a significant weight loss of 23.3% after 48 weeks, as reported at the European Association for the Study of Diabetes annual meeting. This weight loss surpassed the results obtained from individuals taking only Zepbound (14.8%) and those taking the highest dose of eloralintide alone (11.1%). The findings were particularly noteworthy, as patients with diabetes typically experience less weight loss compared to those without diabetes.",
  "summary": "An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}